How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,829 results for

Atrial Fibrillation Acute Management

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Guidance on Acute Management of Atrial Fibrillation in COVID?19 Full Text available with Trip Pro

Guidance on Acute Management of Atrial Fibrillation in COVID?19 Guidance on Acute Management of Atrial Fibrillation in COVID‐19 | Journal of the American Heart Association Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Open Access article Share on Jump to Open Access article Guidance (...) on Acute Management of Atrial Fibrillation in COVID‐19 , MD, , MD, , MD, , MD, , MD, , and MD, and MD1Division of Heart Rhythm Services Department of Cardiovascular Diseases Mayo Clinic Arizona Phoenix AZ Pattara Rattanawong Division of Heart Rhythm Services, , Department of Cardiovascular Diseases, , Mayo Clinic Arizona, , Phoenix, , AZ, , Win Shen Division of Heart Rhythm Services, , Department of Cardiovascular Diseases, , Mayo Clinic Arizona, , Phoenix, , AZ, , Hicham El Masry Division of Heart

2020 American Heart Association

2. Management of Acute Atrial Fibrillation and Atrial Flutter in Non-Pregnant Hospitalized Adults

Management of Acute Atrial Fibrillation and Atrial Flutter in Non-Pregnant Hospitalized Adults Quality Department Guidelines for Clinical Care Inpatient Atrial Fibrillation Guideline Team Team Members Jeffrey M Rohde, MD (Team Lead) Internal Medicine Sarah E Hartley, MD Internal Medicine Sarah Hanigan, PharmD Pharmacy Services Jules Lin, MD Thoracic Surgery Lewis B Morgenstern, MD Neurology (Stroke) F Jacob Seagull, PhD Medical Education David M Somand, MD Emergency Medicine David H Wesorick (...) the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient. Management of Acute Atrial Fibrillation and Atrial Flutter in Non-Pregnant Hospitalized Adults Patient Population. Adult hospitalized patients with Atrial Fibrillation and Flutter. This guideline excludes pregnant women. Objectives. The purpose of these inpatient care guidelines is to provide an evidence-based blue print

2017 University of Michigan Health System

3. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 Full Text available with Trip Pro

are continually evolving and care for patients requires confidence in integrating these new developments into practice. These clinical practice guidelines will assist Australian practitioners in the diagnosis and management of adult patients with AF. Main recommendations: These guidelines provide advice on the standardised assessment and management of patients with atrial fibrillation regarding: screening, prevention and diagnostic work-up; acute and chronic arrhythmia management with antiarrhythmic therapy (...) National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date

2018 MJA Clinical Guidelines

4. Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation EXPERT CONSENSUS DECISION PATHWAY 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force Periprocedural Management of Anticoagulation Writing Committee John U. Doherty, MD, FACC, Chair Ty J. Gluckman, MD, FACC William J (...) for the management of atrial?brillation:anupdateofthe2010ESCGuidelines for the Management of Atrial Fibrillation. Eur Heart J. 2012;33:2719–47. 6. Friberg L, Skeppholm M, Terent A. Bene?t of anti- coagulation unlikely in patients with atrial ?brillation and a CHA 2 DS 2 -VASc score of 1. J Am Coll Cardiol. 2015;65:225–32. 7. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk strati?cation schemes for predicting stroke and thromboembolism in patients with atrial ?brillation: nationwide cohort study. BMJ

2017 American College of Cardiology

5. Atrial fibrillation: management

Atrial fibrillation: management Atrial fibrillation: management Atrial fibrillation: management Clinical guideline Published: 18 June 2014 nice.org.uk/guidance/cg180 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) risk assessment 29 3 Other information 31 3.1 Scope and how this guideline was developed 31 Atrial fibrillation: management (CG180) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 453.2 Incorporated NICE guidance 31 4 The Guideline Development Group, National Clinical Guideline Centre and NICE project team..32 4.1 Guideline Development Group 32 4.2 National Clinical Guideline Centre 33 4.3 NICE project team 33

2014 National Institute for Health and Clinical Excellence - Clinical Guidelines

6. Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

on clinical risk factors, not on AF pattern. Similarly, both the EORP-AF (EURObservational Research Programme–Atrial Fibrillation) General Pilot Registry and the J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) Registry demonstrated higher death rates with nonparoxysmal AF; however, in the multivariable Cox model, nonparoxysmal AF was not an independent predictor of death during follow-up. , In the Euro Heart Survey, paroxysmal AF had comparable risk for thromboembolic events (...) a variety of methods to measure AF burden or recurrence were used. Comprehensive Risk Factor Management Australian investigators reported the results of a study in which participants with AF and body mass index (BMI) ≥27 kg/m 2 opted for comprehensive risk factor management or standard management and were followed up for 15 months, 2 years, and 5 years (LEGACY study [Long-term Effect of Goal-Directed Weight Management on Atrial Fibrillation Cohort: A 5-Year Follow-up Study]). , AF burden was measured

2018 American Heart Association

7. 2016 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation

2016 Focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation Society Guidelines 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Laurent Macle, MD (Co-chair), a John Cairns, MD, b Kori Leblanc, PharmD, c Teresa Tsang, MD, b Allan Skanes, MD, d Jafna L. Cox, MD, e Jeff S. Healey, MD, f Alan Bell, MD, g Louise Pilote, MD, h Jason G. Andrade, MD, a L. Brent Mitchell, MD, i Clare Atzema (...) , Toronto, Ontario, Canada; k The Canadian Stroke Network, Ottawa, Ontario, Canada; l St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada; m Southlake Regional Health Centre, Newmarket, Ontario, Canada ABSTRACT The Canadian Cardiovascular Society (CCS) Atrial Fibrillation (AF) Guidelines Committee provides periodic reviews of new data to pro- duce focused updates that address clinically important advances in AF management. This 2016 Focused Update deals with: (1) the man

2016 CPG Infobase

8. Atrial Fibrillation - Diagnosis and Management

) including the primary prevention of stroke and transient ischemic attack (TIA) in adults aged ≥19 years. This guideline focuses primarily on non-valvular AF. This guideline is part of the - Stroke and Atrial Fibrillation series. The series includes three other guidelines: Stroke and Transient Ischemic Attack – Acute and Long-Term Management ; Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation ; and Warfarin Therapy Management. Key Recommendations Determine (...) and specific medical circumstances of coverage depending on BC PharmaCare plan rules. Diagnostic code: 427.3, I48 Appendices Associated Documents The following documents accompany this guideline: - Stroke and Transient Ischemic Attack – Acute and Long-Term Management - Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation - Warfarin Therapy Management BC Pharmacare - Special Authority Request This guideline is based on scientific evidence current as of the Effective

2015 Clinical Practice Guidelines and Protocols in British Columbia

9. Atrial Fibrillation ? Diagnosis and Management

Fibrillation series. The series includes three other guidelines: Stroke and Transient Ischemic Attack – Acute and Long-Term Management; Use of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Non-Valvular Atrial Fibrillation; and Warfarin Therapy Management. Key Recommendations • Determine the patient’s cardiac stability and provide emergency stabilization if needed. • Consider all patients with atrial fibrillation for antithrombotic therapy (short and long term). • Establish the risk of stroke (...) Fibrillation Symptom Severity with the CCS-SAF Scale • Appendix D: Stroke Risk Assessment in Atrial Fibrillation: CHADS 2 Score • Appendix E: HAS-BLED Score for Major Bleeding • Appendix F: Comparisons of Anticoagulants for Atrial Fibrillation • Appendix G: Prescription Medication Table for Atrial Fibrillation Associated Documents The following documents accompany this guideline: • BCGuidelines.ca – Stroke and Transient Ischemic Attack – Acute and Long-Term Management • BCGuidelines.ca – Use of Non-Vitamin

2015 Clinical Practice Guidelines and Protocols in British Columbia

10. Reveal LINQ insertable cardiac monitor to detect atrial fibrillation after cryptogenic stroke

Reveal LINQ insertable cardiac monitor to detect atrial fibrillation after cryptogenic stroke Re Rev veal LINQ insertable cardiac monitor to detect eal LINQ insertable cardiac monitor to detect atrial fibrillation after cryptogenic strok atrial fibrillation after cryptogenic stroke e Medtech innovation briefing Published: 16 February 2018 nice.org.uk/guidance/mib141 pathways Summary Summary The technology technology described in this briefing is Reveal LINQ insertable cardiac monitor (ICM (...) . The following publications have been identified as relevant to this care pathway: Atrial fibrillation: management (NICE guideline CG180). Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NICE guideline CG68, update in progress). Innovations Reveal LINQ has a proprietary AF detection algorithm with an enhanced p-wave evidence score, which is designed to reduce the false positive detection rate. Reveal LINQ ICM is also smaller than Reveal LINQ insertable cardiac monitor

2018 National Institute for Health and Clinical Excellence - Advice

11. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS

Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 May 19;141(20):1618-1627. doi: 10.1161/CIRCULATIONAHA.120.046534. Epub 2020 Mar 29. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome (...) Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set

2020 EvidenceUpdates

12. Management of Antithrombotic TherApy in Patients With Atrial Fibrillation or DevelOping AtRial Fibrillation During Hospitalization for PCI

relatively frequent occurrence and the many etiologic factors involved in its pathogenetic condition, the frequency and prognostic significance of AF complicating ACS remain unclear Condition or disease Intervention/treatment Acute Coronary Syndrome Atrial Fibrillation Other: Acute coronary syndrome and PCI and AF Detailed Description: There are limited data available, particularly from a representative population-based perspective describing recent pharmacological and non-pharmacological management (...) Management of Antithrombotic TherApy in Patients With Atrial Fibrillation or DevelOping AtRial Fibrillation During Hospitalization for PCI Management of Antithrombotic TherApy in Patients With Atrial Fibrillation or DevelOping AtRial Fibrillation During Hospitalization for PCI - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2018 Clinical Trials

13. Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction. Full Text available with Trip Pro

Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction. The objective of this study was to examine the effects of metoprolol versus diltiazem in the acute management of atrial fibrillation (AF) with rapid ventricular response (RVR) in patients with heart failure with reduced ejection fraction (HFrEF).This retrospective cohort study of patients with HFrEF in AF with RVR receiving either intravenous push (IVP) doses (...) received metoprolol and 34 received diltiazem. The primary outcome, successful rate control within 30 min, occurred in 62% of the metoprolol group and 50% of the diltiazem group (p = 0.49). There was no difference in HR control at predefined time points or incidence of hypotension, bradycardia, or conversion. Although baseline HR varied between groups, maximum median change in HR did not differ. Signs of worsening heart failure were similar between groups.For the acute management of AF with RVR

2018 American Journal of Emergency Medicine

14. 2014 ESC Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting With Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary or Valve Interventions

2014 ESC Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting With Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary or Valve Interventions CURRENTOPINION Managementofantithrombotictherapyinatrial ?brillationpatientspresentingwithacutecoronary syndromeand/orundergoingpercutaneous coronaryorvalveinterventions:ajointconsensus documentoftheEuropeanSocietyofCardiology WorkingGrouponThrombosis,EuropeanHeart RhythmAssociation(EHRA),European (...) , acute coronary syndrome; APT, antiplatelet therapy; CABG, coronary artery bypass graft surgery; CV, cardiovascular; ICH, intracranial haemorrhage; MI, myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; PROBE, prospective, randomized, open, blinded end-point; RCT, randomized controlled trial; STEMI, ST elevation myocardial infarction; TT, triple therapy; UAP, unstable angina pectoris. Antithrombotic management in atrial ?brillation patients with ACS/PCI Page11of25 by guest

2014 Heart Rhythm Society

15. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation Full Text available with Trip Pro

Ischemic Attack; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant. ---- Figure 4 A summary of our recommendations for the management of antithrombotic therapy in patients with atrial fibrillation (AF) in association with Non-ST-elevation acute coronary syndrome (NSTEACS) or ST-elevation myocardial infarction (STEMI). ASA, acetylsalicylic acid (aspirin); CHADS 2 , C ongestive Heart Failure, H ypertension, A ge, D iabetes, S troke/Transient Ischemic Attack; NOAC, non-vitamin K (...) (RCTs) of various antithrombotic therapies among patients with either CAD or AF only, augmented by the results from the available RCTs and observational data from patients with concomitant AF and CAD. x 9 Lip, G.Y., Windecker, S., Huber, K. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group

2016 Canadian Cardiovascular Society

16. HRS White Paper on Atrial Fibrillation Centers of Excellence: Rationale, Considerations, and Goals

. In other cases, patients with AF are managed by noncardiovascular specialists who may have difficulty staying Piccini et al Atrial fibrillation centers of excellence Page 5 of 72 up to date on guideline-directed treatment of AF. It is our belief that a patient-centered, multidisciplinary, and integrated model of care can address all aspects of AF in a manner that should create greater value by improving clinical outcomes and decreasing costs. 26,27 Opportunities to improve care of AF (...) , integrated AF clinic approach to AF management, with a focus on risk factor management, have resulted in reductions in wait times for specialist assessment, emergency department visits, hospitalizations, and mortality. 52 The development of these clinics requires expert staff, collaboration, and special resources that carry significant costs. These requirements limit the widespread initiation of these centers. Piccini et al Atrial fibrillation centers of excellence Page 7 of 72 Section 3 Building

2020 Heart Rhythm Society

17. New-onset atrial fibrillation

palpitations, dyspnoea, angina, dizziness or syncope, and features of congestive heart failure (CHF), tachycardia-induced cardiomyopathy, stroke, and death. ECG shows absent P waves, presence of fibrillatory waves, and irregularly irregular QRS complexes. Most patients presenting with new-onset or 'acute' atrial fibrillation (AF) do not require immediate cardioversion. Most patients will require medical therapy to control ventricular rate. Patients who develop haemodynamic compromise should have immediate (...) is intact. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269-e367. http://circ.ahajournals.org/content/123/10/e269.long http://www.ncbi.nlm.nih.gov/pubmed/21382897?tool=bestpractice.com New-onset AF is defined as a new onset

2018 BMJ Best Practice

18. Acute management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with decompensated/acute heart failure

Acute management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with decompensated/acute heart failure Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne (...) will be used to account for anticipated heterogeneity. ">Effect models Example: Heterogeneity will be assessed using the (residual) I2 and adjusted R2 statistics. ">Heterogeneity For further guidance please refer to the and to pre-clinical meta-analysis. Example: Whenever a control group serves more than one experimental group, we will correct the total number of control animals in the meta-analysis by dividing the number of animals in the control group by the number of treatment groups served. Where

2018 PROSPERO

19. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial Full Text available with Trip Pro

Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI.Using a 2×2 (...) in patients with atrial fibrillation who have ACS, whether managed medically or with PCI, and those undergoing elective PCI compared with regimens that include vitamin K antagonists, aspirin, or both.URL: https://www.clinicaltrials.gov. Unique identifier: NCT02415400.

2019 EvidenceUpdates

20. The future of atrial fibrillation management: integrated care and stratified therapy. Full Text available with Trip Pro

a challenge, as shown by patients who are only diagnosed with the condition when admitted to hospital for acute cardiac decompensation or stroke. Once diagnosed, atrial fibrillation requires chronic, multidimensional management in five domains (acute management, treatment of underlying and concomitant cardiovascular conditions, stroke prevention therapy, rate control, and rhythm control). The consistent provision of these treatment options to all patients with atrial fibrillation is difficult, despite (...) The future of atrial fibrillation management: integrated care and stratified therapy. Atrial fibrillation is one of the major cardiovascular health problems: it is a common, chronic condition, affecting 2-3% of the population in Europe and the USA and requiring 1-3% of health-care expenditure as a result of stroke, sudden death, heart failure, unplanned hospital admissions, and other complications. Early diagnosis of atrial fibrillation, ideally before the first complication occurs, remains

2017 Lancet

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>